Reducing Avoidable Protocol Amendments by Anticipating Operational Pitfalls Hidden in Clinical Trial Design

Protocol amendments are a costly but common part of clinical trials, often reflecting gaps between scientific ambition and real-world execution.

Drawing from Advarra’s operational dataset of more than 30,000 studies and nearly 70,000 unique amendments since 2019, this report identifies key drivers for amendments, and how they differ across six therapeutic areas: Autoimmune, Cardiovascular, Gastrointestinal, Infectious disease, Oncology, and Rare Disease.

In this report, you will:

• Discover how amendment rates vary by therapeutic area and where risk is highest.
• Identify the distinct and predictable drivers of change between original protocols and amended protocols, including endpoints, eligibility criteria, and visit schedules.
• Access actionable recommendations to improve protocol feasibility and reduce amendment risk before your study begins.

By applying these operational insights early, sponsors and CROs can anticipate risks, improve protocol feasibility, and reduce avoidable amendments.